Global Antibiotic Resistance Market Research Report 2022: 6 Key Large Opportunities in this Space and Developed Market Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–That “Antibiotic Resistance Markets – Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive and Investor Guides, and Adaptation.” Report has been added ResearchAndMarkets.com Offer.

The report has identified 6 key major opportunities in this space and developed market forecasts.

Antimicrobial resistance creates new types of infections and superbugs that are resistant to current antibiotic drugs. New technologies (and new drugs) are being developed to capture this growing market.

The report has also delved into the technology, giving you an understanding in plain language of the different ways of treating pathogens and infections, including an explanation of the key role that diagnostics will play. This is a multi-player market, the report features over 100 biotechnology companies. The report summarizes which technologies they use.

Make investment decisions and reviews with confidence based on the latest data. The report contains market forecasts for five years.

Main topics covered:

Overview of a dynamic market

Market Players – Roles and Impact

  • Drug Manufacturers – Larger/Pharmaceutical

  • Drug Manufacturers – Generics

  • contract research and manufacturing

  • In vitro diagnostics industry

  • drug marketing company

  • biotechnology company

  • regulators

Understanding antimicrobial resistance

  • What is Antimicrobial Resistance (AMR)

  • bacteria and other microbes

  • The History of Antibiotics

  • The role of animal husbandry

  • The effects of horizontal transfer

  • The threat of AMR

The changing path to new antibiotics and technologies

The key role of diagnostics in AMR

The market opportunity of AMR

Key Big Market Opportunities in AMR

  • Streptococcus pneumoniae (DRSP)

  • Campylobacter (DRC)

  • Clostridium difficile (CD)

  • Staphylococcus aureus (MRSA)

  • Neisseria gonorrhoeae (DRNG)

  • Salmonella (DRNTS)

Development opportunities for therapeutic technologies

  • Use of viruses against bacteria

  • Hydrolytic enzymes join the fight

  • antibody

  • vaccinations

  • Probiotic Technology

  • Peptides vs. Pathogens

  • Mining outdated science

  • CRISPR antibiotics

Antimicrobial Resistance Recent Developments

  • AMR Pandemic Overlooked

  • New resistance-breaking antibiotic combination

  • CDC awards $22 million to fight antibiotic resistance

  • Antibiotic resistance outsmarted by supercomputers

  • STIs reach record highs

  • New research using nanoparticles to boost dwindling antibiotics

  • OpGen Receives FDA Clearance for AMR Panel

  • CDC updates STI diagnosis, treatment guidelines

  • Positive associations between AM use in animals and AMR in humans

  • Results of the PEW Antibiotics Pipeline

Major biotechnology companies and their technology

  • Melinta Therapeutics

  • Arzanis

  • Phage Technologies SA

  • Westway Health

  • Tetraphase Pharmaceuticals

  • BioVersys GmbH

  • Nabriva therapeutics

  • macrolide pharmaceuticals

  • Nemesis Bioscience

  • C3J Therapeutics, Inc.

  • EpiBiome

  • to discuss

  • SmartPhage.

  • AmpliPhi Life Sciences

  • Pherecycles Pharma

  • microphones

  • Procarta Biosystems

  • lumavita

  • woman therapeutics

  • Priaxon

  • Biolytx Pharma

  • AntibioTx

  • Xellia Pharmaceuticals

  • Paratek Pharma

  • Synereca Pharma

  • Allecra therapeutics

  • Fixed phage

  • Enanta Pharmaceuticals, Inc.

  • Demuris

  • Prommun

  • biosergic

  • Innovation Pharma

  • Aviragen therapeutics

  • Achillion Pharma

  • ImmunNovative Developments, SL

  • Achaogen, Inc.

  • SelectX Pharmaceuticals, Inc.

  • TaiGen Biotechnology Co.,Ltd.

  • Theravance Biopharma

  • abbie

  • Kyorin Pharmaceutical Co.,Ltd.

  • Iterum Therapeutics Limited

  • forge therapeutics

  • Alopexx Vaccine LLC

  • Integrated biotherapeutics

  • Hennepin Life Sciences

  • Fedora Pharmaceuticals Inc.

  • Contract Corporation

  • Basilea Pharmaceutica Ltd

  • AiCuris

  • Red Hill Biopharma

  • Redx Pharma Plc/Redx Anti-Infectives Ltd.

  • ABAC Therapeutics

  • Alaxia SAS

  • Antibio SAS

  • Auspherix Ltd

  • BioFilm Pharma

  • Centauri Therapeutics Ltd

  • Combioxin SA

  • From Volterra

  • Debiopharm International SA

  • Deinobiotics/Deinove

  • Destiny Pharma plc

  • I choose life sciences

  • Helper by Therapeutics Ltd

  • Karveel Pharmaceuticals

  • Maat Pharma

  • Motiv BioSciences, Inc / Motiv Bio PLC

  • CHANGE IN SAS

  • Neem Biotech Ltd

  • Northern Antibiotics Oy (Ltd)

  • nosopharm

  • NovaBiotics Ltd

  • Phico Therapeutics Ltd

  • Polyphor Ltd

  • QureTech Bio AB

  • SetLance srl

  • Ultupharma AB

  • Vaxdyn

  • vibiosphene

  • Bioaster

  • Vivexie

  • KBP Life Sciences

  • Absynth Biologics

  • Spero therapeutics

  • note

  • symphogen

  • Warp Drive Bio.

  • Johnson & Johnson

  • Pfizer

  • allergy

  • GlaxoSmithKline

  • Novartis

  • Gilead Sciences

  • AstraZeneca

  • Sanofi

  • Shionogi Inc.

  • Cipla

  • DSM Sinochem Pharmaceuticals

  • Wockhardt GmbH

  • VenatoRx Pharmaceuticals

  • MicuRx

  • Entasis Therapeutics

  • Merlion Pharmaceuticals

  • Aridis Pharmaceuticals Inc.

For more information about this report, see https://www.researchandmarkets.com/r/mweczd

Leave a Comment